Use of phosphorothioate-modified oligodeoxynucleotides to inhibit NF-κB expression and lymphocyte function

Clinical Immunology and Immunopathology

Volumn 86, Issue 2, 1998, Pages 170-179

  Khaled, Annette R ^a   Butfiloski, Edward J ^b   Sobel, Eric S ^b   Schiffenbauer, Joel ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Antisense; Autoimmunity; Decoy; Immunotherapy; NF B

Indexed keywords

CARISOPRODOL; DNA ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 2; INTERLEUKIN 6; MESSENGER RNA; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; TRANSCRIPTION FACTOR;

ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE FUNCTION; PRIORITY JOURNAL; SPLEEN CELL;

EID: 0032005346     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1997.4486     Document Type: Article

References (36)

1. Sen R., Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell. 46:1986;705-716.
2. Baldwin A. S. Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 14:1996;649-683.
3. Kunsch C., Ruben S. M., Rosen C. A. Selection of optimal kappa B/Rel DNA-binding motifs: Interaction of both subunits of NF-kappa B with DNA is required for transcriptional activation. Mol. Cell Biol. 12:1992;4412-4421.
4. Baeuerle P. A., Baltimore D. Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-kappa B transcription factor. Cell. 53:1988;211-217.
5. Hohmann H. P., Remy R., Scheidereit C., van Loon A. P. Maintenance of NF-kappa B activity is dependent on protein synthesis and the continuous presence of external stimuli. Mol. Cell Biol. 11:1991;259-266.
6. Hoyos B., Ballard D. W., Bohnlein E., Siekevitz M., Greene W. C. Kappa B-specific DNA binding proteins: role in the regulation of human interleukin-2 gene expression. Science. 244:1989;457-460.
7. Libermann T. A., Baltimore D. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol. Cell Biol. 10:1990;2327-2334.
8. Collart M. A., Baeuerle P., Vassalli P. Regulation of tumor necrosis factor alpha transcription in macrophages: Involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-kappa B. Mol. Cell Biol. 10:1990;1498-1506.
9. Altman A., Theofilopoulos A. N., Weiner R., Katz D. H., Dixon F. J. Analysis of T cell function in autoimmune murine strains: Defects in production and responsiveness to interleukin 2. J. Exp. Med. 154:1981;791-808.
10. Finck B. K., Chan B., Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J. Clin. Invest. 94:1994;585-591.
11. Saxne T., Palladino M. A. Jr., Heinegard D., Talal N., Wollheim F. A. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum. 31:1988;1041-1045.
12. Keffer J., Probert L., Cazlaris H., Georgopoulos S., Kaslaris E., Kioussis D., Kollias G. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis. EMBO J. 10:1991;4025-4031.
13. Fujisawa K., Aono H., Hasunuma T., Yamamoto K., Mita S., Nishioka K. Activation of transcription factor NF-kappa B in human synovial cells in response to tumor necrosis factor alpha. Arthritis Rheum. 39:1996;197-203.
14. Sakurada S., Kato T., Okamoto T. Induction of cytokines and ICAM-1 by proinflammatory cytokines in primary rheumatoid synovial fibroblasts and inhibition byNL. Int. Immunol. 8:1996;1483-1493.
15. Agrawal S. Antisense oligonucleotides: Towards clinical trials. Trends. Biotechnol. 14:1996;376-387.
16. Sharma H. W., Narayanan R. The therapeutic potential of antisense oligonucleotides. Bioessays. 17:1995;1055-1063.
17. Bielinska A., Shivdasani R. A., Zhang L. Q., Nabel G. J. Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. Science. 250:1990;997-1000.
18. Matsukura M., Shinozuka K., Zon G., Mitsuya H., Reitz M., Cohen J. S., Broder S. Phosphorothioate analogs of oligodeoxynucleotides: Inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA. 84:1987;7706-7710.
19. Sharma H. W., Perez J. R., Higgins Sochaski K., Hsiao R., Narayanan R. Transcription factor decoy approach to decipher the role of NF-kappa B in oncogenesis. Anticancer Res. 16:1996;61-69.
20. Merino R., Fossati L., Izui S. The lupus-prone BXSB strain: The Yaa gene model of systemic lupus erythematosus. Springer Semin. Immunopathol. 14:1992;141-157.
21. Khaled A. R., Soares L. S., Butfiloski E. J., Stekman I., Sobel E. S., Schiffenbauer J. Inhibition of the p50 (NFκB1) subunit of NF-κB by phosphothioate-modified antisense oligodeoxynucleotides reduces NF-κB expression and immunoglobulin synthesis in murine B cells. Clin. Immunol. Immunopathol. 83:1997;254-262.
22. Higgins K. A., Perez J. R., Coleman T. A., Dorshkind K., McComas W. A., Sarmiento U. M., Rosen C. A., Narayanan R. Antisense inhibition of the p65 subunit of NF-kappa B blocks tumorigenicity and causes tumor regression. Proc. Natl. Acad. Sci. USA. 90:1993;9901-9905.
23. Narayanan R., Higgins K. A., Perez J. R., Coleman T. A., Rosen C. A. Evidence for differential functions of the p50 and p65 subunits of. Mol. Cell Biol. 13:1993;3802-3810.
24. Sokoloski J. A., Sartorelli A. C., Rosen C. A., Narayanan R. Antisense oligonucleotides to the p65 subunit of NF-kappa B block. Blood. 82:1993;625-632.
25. Neurath M. F., Pettersson S., Meyer zum Buschenfelde K. H., Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat. Med. 2:1996;998-1004.
26. Stein C. A. Does antisense exist? Nat. Med. 1:1995;1119-1121.
27. Maltese J. Y., Sharma H. W., Vassilev L., Narayanan R. Sequence context of antisense RelA/NF-kappa B phosphorothioates determines specificity. Nucleic Acids. Res. 23:1995;1146-1151.
28. Sharma H. W., Hsiao R., Narayanan R. Telomerase as a potential molecular target to study G-quartet phosphorothioates. Antisense. Nucleic Acid. Drug Dev. 6:1996;3-7.
29. Krieg A. M., Yi A. K., Matson S., Waldschmidt T. J., Bishop G. A., Teasdale R., Koretzky G. A., Klinman D. M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:1995;546-549.
30. Zhao Q., Temsamani J., Iadarola P. L., Jiang Z., Agrawal S. Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem. Pharmacol. 51:1996;173-182.
31. Eck S. L., Perkins N. D., Carr D. P., Nabel G. J. Inhibition of phorbol ester-induced cellular adhesion by competitive binding of NF-kappa B in vivo. Mol. Cell Biol. 13:1993;6530-6536.
32. Goldring C. E., Narayanan R., Lagadec P., Jeannin J. F. Transcriptional inhibition of the inducible nitric oxide synthase gene by competitive binding of NF-kappa B/Rel proteins. Biochem. Biophys. Res. Commun. 209:1995;73-79.
33. Gilkeson G. S., Ruiz P., Pippen A. M., Alexander A. L., Lefkowith J. B., Pisetsky D. S. Modulation of renal disease in autoimmune NZB/NZW mice by immunization with bacterial DNA. J. Exp. Med. 183:1996;1389-1397.
34. Lai J. H., Horvath G., Subleski J., Bruder J., Ghosh P., Tan T. H. RelA is a potent transcriptional activator of the CD28 response element within the interleukin 2 promoter. Mol. Cell Biol. 15:1995;4260-4271.
35. Beg A. A., Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science. 274:1996;782-784.
36. Nakayama K., Shimizu H., Mitomo K., Watanabe T., Okamoto S., Yamamoto K. A lymphoid cell-specific nuclear factor containing c-Rel-like proteins preferentially interacts with interleukin-6 kappa B-related motifs whose activities are repressed in lymphoid cells. Mol. Cell Biol. 12:1992;1736-1746.